US Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

首页> 外文期刊>Clinical infectious diseases >US Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

【24h】

US Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

机译：美国食品药品监督管理局批准吉利德公司的Epclusa（Sofosbuvir / Velpatasvir）用于治疗所有基因型的慢性丙型肝炎

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical infectious diseases》 |2016年第7期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. US Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C [J] . Clinical infectious diseases . 2016,第7期

机译：美国食品药品监督管理局批准吉利德公司的Epclusa（Sofosbuvir / Velpatasvir）用于治疗所有基因型的慢性丙型肝炎
2. sofosbuvir + velpatasvir (epclusa0) in chronic hepatitis C An advance in HCV genotype 2 infection [J] . Prescrire international . 2018,第192期

机译：Sofosbuvir + Velpatasvir（EPClusa0）在慢性丙型肝炎中HCV基因型2感染
3. Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation [J] . Struble Kimberly, Chan‐Tack Kirk, Qi Karen, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2018,第2期

机译：基于患者人口和丙型肝炎病毒基因型的Sofosbuvir / Velpatasvir / Voxilaprevir的受益风险评估：美国食品和药物管理局的评价
4. Genotype and Serotype Identification of Hepatitis B Virus in Chronic Hepatitis B Patients Treated with Telbivudine [C] . Y Purnamasari, Tien, Arimaswati, International Seminar on Smart Molecule of Natural Resources . 2020

机译：临床治疗慢性乙型肝炎患者乙型肝炎病毒的基因型和血清型鉴定
5. Hepatitis C infection in injection drug users from southern China: Low viral clearance, multiple genotypes and mixed genotype infections. [D] . Garten, Rebecca JoAnne. 2005

机译：中国南部注射吸毒者的丙型肝炎感染：病毒清除率低，多种基因型和混合基因型感染。
6. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India [O] . Yashika Chugh, Radha Krishan Dhiman, Madhumita Premkumar, 2012

机译：在印度旁遮普邦的全民覆盖计划中，泛基因型Sofosbuvir-Velpatasvir组合与基因型依赖性直接作用抗病毒药物治疗丙型肝炎的真实成本效益
7. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India [O] . Yashika Chugh, Radha Krishan Dhiman, Madhumita Premkumar, 2019

机译：Pan-Genotypic Sofosbuvir-Velpatasvir组合与基因型直接作用抗病毒药物的实际成本效果，用于治疗印度旁遮普邦普遍覆盖计划的丙型肝炎患者

US Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

著录项

相似文献

相关主题

期刊订阅